Small Cap Insights

In-depth analysis and expert insights into small-cap companies with high growth potential.

EnergyTechnologySmall Cap InsightsBiotechnology & HealthcareAnalytica Alpha Mining & Metals
Small Cap InsightsSmall Cap Insights
+1+1
📊 Policy Noise Masks Big Moves

📊 Policy Noise Masks Big Moves

Biotech dilution, AI milestones, and robotics trades are reshaping the tape

Matthias Schneider
Small Cap InsightsSmall Cap Insights
+1+1
📊 Commodities Up, Policy Risks Ahead

📊 Commodities Up, Policy Risks Ahead

Offerpad volume jumps 136% as speculative flows hit housing and fintech

Matthias Schneider
Small Cap InsightsSmall Cap Insights
+1+1
📊 Risk-On Revival Faces Tests

📊 Risk-On Revival Faces Tests

AREC rallies 23% on rare-earth supply deal

Matthias Schneider
EnergyEnergy
+2+2
⚡️ Retail Sees Opportunity Where Wall Street Sees Risk

⚡️ Retail Sees Opportunity Where Wall Street Sees Risk

Missed earnings, rising margins, retail conviction—why Canadian Solar could be undervalued.

Matthias Schneider
Small Cap InsightsSmall Cap Insights
+1+1
📊 Jackson Hole Jitters Rise

📊 Jackson Hole Jitters Rise

Rate-sensitive small caps wobble, awaiting clarity from the Fed’s next move

Matthias Schneider
Small Cap InsightsSmall Cap Insights
+1+1
📊 At A Crossroads

📊 At A Crossroads

Caution on rate cuts collides with double-digit gains in CGTX and AXTI

Matthias Schneider
Small Cap InsightsSmall Cap Insights
+1+1
📊 Rally Running Thin

📊 Rally Running Thin

Kandi’s first CATL order sparks a 13% surge

Matthias Schneider
Small Cap InsightsSmall Cap Insights
+1+1
📊 All Eyes on Powell

📊 All Eyes on Powell

No press release, no catalyst— ImmunoPrecise blasts higher

Matthias Schneider
Small Cap InsightsSmall Cap Insights
+1+1
📊 Small-Cap Trends at Risk

📊 Small-Cap Trends at Risk

IO Biotech’s 69% leap highlights both promise and fragility in small caps

Matthias Schneider
TechnologyTechnology
+1+1
📱 Japan Proves the Model — The U.S. Is Next

📱 Japan Proves the Model — The U.S. Is Next

They conquered the toughest comics market in the world. Now they are taking aim at the home of Marvel and DC.

Matthias Schneider
Small Cap InsightsSmall Cap Insights
+1+1
📊 Biotech Holds Modest Gains

📊 Biotech Holds Modest Gains

Positive Phase 2 feedback ignites sharp move in neuro-focused biotech

Matthias Schneider
Small Cap InsightsSmall Cap Insights
+1+1
📊 Rotation Fuels Sector Strength

📊 Rotation Fuels Sector Strength

Investor buzz builds after biotech scores key clinical milestone

Matthias Schneider